Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved tamoxifen for reimbursement as a treatment option for the adjuvant treatment of estrogen receptor positive breast cancer in patients who are pre- or post-menopausal women.
This is written in the approval document as:
Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | ER positive | Invasive Breast Carcinoma | Tamoxifen |